Waystar CEO Matthew Hawkins Executes $4.14‑$26.23 Insider Buy‑Sell Strategy

Corporate News – Insider Activity Spotlight: Waystar Holding Corp.

Recent Insider Move

On October 6 2026, Waystar Holding Corp. Chief Executive Officer Matthew Hawkins executed a Rule 144 transaction that involved the purchase of 82,500 shares of the company’s common stock at $4.14 per share, immediately followed by a sale of the same quantity at $26.23 per share. The rapid buy‑sell sequence, completed within the same filing period, strongly suggests a pre‑planned, rule‑based transaction. It appears to be structured under a 10b‑5(b)(1)(c) plan that locks in a sale price while preserving the ability to reacquire the shares at a lower price. The timing of the trade coincides with the company’s recent stock‑price rebound (1.74 % weekly, 6.35 % monthly), enabling Hawkins to capitalize on a price uptick while maintaining his overall equity stake.

Implications for Investors

The move signals short‑term confidence in the company’s valuation trajectory. By buying at $4.14 and selling at $26.23, the CEO demonstrates a belief that Waystar’s shares are worth far more than recent intraday lows. The execution via a Rule 144 plan also indicates a commitment to share liquidity and transparency, potentially reducing the perception of insider speculation. Investors should note that, although the transaction is routine, it highlights Hawkins’ willingness to use structured plans to manage his holdings in a volatile healthcare environment—an environment that has seen the stock drop 31.13 % year‑to‑date.

CEO Profile: A Pattern of Strategic Equity Management

Hawkins has a long history of disciplined insider activity. Since early 2025, he has routinely bought and sold shares in blocks of 82,500 and 60,038, often employing Rule 144 or Rule 10b‑5(b)(1)(c) plans to mitigate market impact. His activity shows a preference for buying at lower prices (e.g., $4.14 in March 2025 and August 2025) and selling near or above the current market rate (e.g., $25.73–$26.23 in September–October 2026). Additionally, he has actively exercised stock options in large volumes (over 82,500 shares in October 2026), suggesting a strategy of converting options to cash when the price exceeds a target threshold. This pattern reflects a CEO who balances long‑term equity ownership with periodic liquidity events—a practice common among leaders of growing healthcare companies seeking to fund expansion while maintaining shareholder confidence.

Company‑Wide Insider Trends

Beyond Hawkins, Waystar’s board and senior leadership have exhibited moderate insider activity. Chief Product & AI Officer William Chan recently sold a block of shares in a sell‑to‑cover transaction, while other executives have made modest purchases and sales, often tied to vesting schedules and tax‑deferral strategies. The overall insider transaction volume has remained within regulatory limits and has not disrupted the stock’s broader market dynamics, indicating that the company’s governance framework is effectively managing equity distribution among its leadership.

Looking Ahead

With the stock’s 52‑week high at $40.35 and a current market cap of $5.08 billion, Waystar is positioned in a competitive healthcare landscape where strategic investments and disciplined capital allocation are key. Hawkins’ recent buy‑sell activity underscores a willingness to align personal gains with corporate performance. For investors, this signals a CEO who actively monitors market conditions and employs structured plans to maintain liquidity without compromising long‑term ownership—a prudent approach that may bode well for Waystar’s future growth prospects.

Transaction Summary